No holiday for Regenera shareholders as firm re-jigs merger
07 December, 2005 by Helen SchullerShareholders in Regenera (ASX:RGA) have been asked to attend a meeting in Perth between Christmas and New Year, as the company seeks to revise terms of its planned merger with US firm Advanced Ocular Systems (AOS).
New Biota CEO speaks of road ahead
07 December, 2005 by Ruth BeranOn Friday, Biota Holdings (ASX:BTA) introduced Peter Cook as its new CEO and managing director, replacing Peter Molloy. On his first day at the company, Cook spoke with Ruth Beran about his background, the future for the company and the similarities between orbital engines and biotechnology.
Domantis, Bristol-Myers Squibb form partnership
06 December, 2005 by Graeme O'NeillUK firm Domantis, 36 per cent owned by Peptech (ASX:PTD), has signed an agreement with global pharma Bristol-Myers Squibb (NYSE:BMY) to develop domain-antibody (dAb) therapeutics for multiple immunology and cancer targets.
Prima receives first payment from Arthron sale
05 December, 2005 by Ruth BeranPrima Biomed (ASX:PRR) has received the first payment of US$500,000 from Toronto-based immunology company Trillium Therapeutics following the settlement of the sale of Prima's subsidiary Arthron.
Anadis claims success with anthrax killer
05 December, 2005 by Graeme O'NeillMelbourne biopharma Anadis (ASX:ANX) has announced that antibody extracts from the colostrum of immunised dairy cows completely protects cells from the lining of the human lung against deadly anthrax toxin in vitro.
Medical Therapies closes IPO offer oversubscribed
02 December, 2005 by Helen SchullerMedical Therapies has completed its IPO capital raising over-subscribed and is likely to list on the ASX on December 9. This is the fourth listing date for the company which issued a replacement prospectus following an unsuccessful attempt to list on the ASX in August.
Former Fauldings exec takes helm at Biota
02 December, 2005 by Ruth BeranPeter Cook is Biota Holdings' (ASX:BTA) new CEO and managing director, starting next Friday.
Neuren raises $6.4m in share placement
02 December, 2005 by Helen SchullerAuckland biopharma Neuren Pharmaceuticals (ASX: NEU) has raised AUD$6.36 million to fund the acceleration of the clinical trial program for Glypromate and NNZ-2566.
Psivida launches food technology spinout
01 December, 2005 by Ruth BeranPerth-based bio-nanotech company Psivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has created a new spinout company, PsiNutria, to develop its silicon technology in the food industry.
New study finds brains behind social phobia
01 December, 2005 by Graeme O'NeillNew research common condition known as social phobia, in which individuals show a heightened response to threatening faces, or perceive normal social situations as threatening, is associated with heightened activity of the brain's 'fear centre', the amygdala.
New Epitan CEO sees IND soon
01 December, 2005 by Ruth BeranAfter a sudden change of management earlier this week, Melbourne-based Epitan (ASX:EPT, ADR:EPTNY, XETRA:UR9) has entered the "final stretch" in the process of lodging an IND application with the FDA for Epitan's lead drug EPT1647, according to newly-appointed CEO Dr Philippe Wolgen.
Select Vaccines to raise $1.79m
29 November, 2005 by Helen SchullerMelbourne's Select Vaccines (ASX:SLT) is planning to raise AUD$1.79 million through a rights issue and placement to provide working capital for the development of a vaccine against hepatitis C and further development of diagnostic assays.
US$1m milestone payment for BioDiem
29 November, 2005 by Helen SchullerMelbourne-based flu vaccine company BioDiem (ASX:BDM) has received a payment of US$1 million (AUD$1.35 million) from Akzo Nobel's Nobilon, bringing its total milestone payments to US$3 million.
Unknown party lists Psiron on Berlin-Bremen stock exchange
29 November, 2005 by Ruth BeranThe Berlin-Bremen stock exchange in Germany has advised Psiron (ASX:PSX) that a third party has applied for the Sydney-based oncology therapy developer's shares to be listed on Freiverkehr, the stock exchange's third market segment.
Virax aims to raise $3.85m after NIH disappointment
28 November, 2005 by Helen SchullerMelbourne immunotherapy developer Virax Holdings (ASX:VHL) has lodged a prospectus to raise AUD$3.85 million through a rights issue for the further development of its HIV therapeutic vaccine VIR201 following its unsuccessful bid for US NIH funding.
